Post Profile

In a phase I clinical trial, patients with previously treated advanced non-small cell lung cancer (NSCLC) have showed initial response and disease control from the drug combination of ramucirumab and pembrolizumab. Roy S. Herbst, MD, PhD, Chief of Medical Oncology at Yale Cancer Center and Smilow Cancer Hospital at Yale New Haven, will present the interim data of the clinical trial at the European Society for Medical Oncology (ESMO) Congress today.
read more


Related Posts

Merkel cell carcinoma patients who received pembrolizumab often had durable responses

Health : Newswise Medical News

In a phase 2 clinical trial of the immunotherapy drug pembrolizumab as a first-line systemic therapy for advanced Merkel cell carcinoma, or MCC - a rare, aggressive type of skin cancer - the clinical response rate was similar to tha...

New Drug Approved For Treatment Of Non Small Cell Lung Cancer In Specific Patient Population

Health : Medical News Today

Lung Cancer Alliance (LCA) applauds the Food and Drug Administration (FDA) approval of Xalkori (crizotinib) with non-small cell lung cancer (NSCLC) who are ALK positive. The drug was approved based on data from two clinical trials, ...

NovaRx Initiates Pivotal Phase III Clinical Trial In Lung Cancer Patients

Health : Medical News Today

NovaRx Corporation announced that the company initiated its pivotal Phase III clinical trial of Lucanix(R) (belagenpumatucel-L) in the treatment of advanced non-small cell lung cancer (NSCLC). The first patient enrolled in the study...

Endocyte Announces Positive Interim Results From Phase II Clinical Trial Of EC145 In Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Health : Medical News Today

Endocyte Inc. has announced positive interim results from an ongoing Phase II clinical study of EC145 in patients with advanced non-small cell lung cancer (NSCLC). The single arm Phase II study is designed to evaluate treatment with...

Pembrolizumab new option for first line treatment of patients with advanced lung cancer and high PD-L1 expression

Diseases & Conditions / Cancer : ScienceDaily: Cancer

Pembrolizumab is set to become a new option for first line treatment of patients with advanced lung cancer and high PD-L1 expression, according to the results of the phase III KEYNOTE-024 trial.


Copyright © 2016 Regator, LLC